Lupin Limited (LUPIN) — Announcement

📢 Key Event
Lupin receives tentative FDA approval for Enzalutamide Tablets

Lupin announced it received tentative U.S. FDA approval for its Abbreviated New Drug Application for Enzalutamide Tablets in 40 mg, 80 mg, 120 mg, and 160 mg strengths, providing alternative dosing options compared to the reference listed drug Xtandi. The approval covers bioequivalence for the 40 mg and 80 mg strengths and introduces new higher-dose formulations. This regulatory milestone expands Lupin's portfolio in the U.S. oncology market and positions it for potential commercial launch pending final approval, enhancing revenue diversification and growth prospects in a high-value therapeutic area.

📄 View Original Announcement (PDF)

📊 Stock Analysis — LUPIN ✨ Ask AI About This